Anthem Biosciences Q1 FY27 earnings call: Revenue & Margins
Q1 FY27 earnings call: what management said on revenue, margins and capex.
- Revenue
- ₹418Cr
- −22.6% YoY
- −31.6% QoQ
- Net profit
- ₹120Cr
- −11.8% YoY
- −36.8% QoQ
- Margin
- 36%
- +1 pp YoY
- −8 pp QoQ
Guidance rank: #66 of 87 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
What the Q1 FY27 call signalled
1 of 3 strong
The short version
Anthem expects overall growth for FY27 to remain intact and consistent with its historical double-digit performance. Q1 FY27 was a soft quarter due to timing shifts in deliveries; business is cyclical with lumpiness expected in quarterly performance.
From Anthem Biosciences Ltd's Q1 FY27 earnings-call transcript · updated 23 Sept 2026.
Revenue & Sales Performance
- Anthem expects overall growth for FY27 to remain intact and consistent with its historical double-digit performance.
- Q1 was a soft quarter with about a 25% YoY decline, but Q2, Q3, and Q4 are expected to see recovery and growth.
- The business is characterized by quarterly fluctuations (lumpiness) due to customer delivery scheduling.
- A strong order book with about 60% visibility for the full year provides confidence in achieving growth targets.
- Growth in specialty ingredients, affected by supply chain pressures, is expected to recover strongly by year-end.
- New customers, including a recently added Big Pharma client, and increased volumes from existing clients will contribute to growth.
2 more points from Anthem Biosciences Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Anthem Biosciences Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Unit 4 Expansion:
- Total capex outlay: Approximately Rs. 1,200 crores for Phase 1.
- Property size: 30 acres; Phase 1 uses half the area.
- Capacity addition: 365 kiloliters custom synthesis, 100 kiloliters fermentation, plus food and nutra plant.
- Timeline: Construction started last year; expected completion by end of FY28.
- Capex split: Roughly 50% each in FY27 and FY28.
- Current status: Civil works nearly complete; equipment orders to begin.
- FY27 Capex:
- Targeted around Rs. 700 crores, mainly for Unit 4.
- Post FY28:
- Capex expected to decline after Unit 4 is commissioned.
2 more points from Anthem Biosciences Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Anthem Biosciences Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- At the start of FY27, Anthem had about 60% of its order book for the full year's delivery already secured.
- After Q1, despite a muted quarter, the order book was replenished and still stands at approximately 60%.
- This 60% visibility covers the entire business, including CRDMO, specialty ingredients, and R&D segments.
- The remaining 40% of the order book typically comes from onboarding new customers or increased volumes from existing clients.
- Orders are a mix of confirmed and anticipated purchase orders, with rolling forecasts updated every 3 to 6 months.
2 more points from Anthem Biosciences Ltd's call on order book
Create a free account to keep reading this call
Anthem Biosciences Ltd — Quarterly revenue & net profit
Anthem Biosciences Ltd Q1 FY27 results — key figures
| ₹ Cr | Q1 FY27 | Q1 FY26 | YoY | Q4 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue | 418 | 540 | -22.6% | 611 | -31.6% |
| Operating profit (EBITDA) | 151 | 191 | -20.9% | 267 | -43.4% |
| Operating margin | 36% | 35% | +1 pp | 44% | -8 pp |
| Profit before tax | 145 | 186 | -22% | 278 | -47.8% |
| Net profit (PAT) | 120 | 136 | -11.8% | 190 | -36.8% |
| EPS (₹) | 2.13 | 2.42 | -12% | 3.38 | -37% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹594 Cr, net profit ₹211 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Anthem Bioscienc's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- KRM Ayurveda (Q1 FY27)
Total income for Q1 FY27: ₹3,286.55 Lakhs, +32.4% YoY . Key investor presentation takeaways from KRM Ayurveda Ltd's Q1 FY27 investor presentation — and how it r
- Balaxi Pharma (Q1 FY27)
Q1 FY27 Revenue: ₹80.68 crore, up 14.1% YoY from ₹70.74 crore in Q1 FY26 (Page 20). Key investor presentation takeaways from Balaxi Pharma's Q1 FY27 investor pr
- Sanjivani Paranteral (Q1 FY27)
Q1 FY27 consolidated revenue from operations: ₹238.39 Mn, up 33.8% YoY from ₹178.92 Mn in Q1 FY26 (Page 25). Key investor presentation takeaways from Sanjivani
- Natural Capsules (Q1 FY27)
Revenue from Operations for Q1FY27: ₹48.71 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q1 FY27 investor presentation — and how it ra
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Anthem Biosciences Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Anthem Biosciences Ltd Q1 FY27 results?
Anthem expects overall growth for FY27 to remain intact and consistent with its historical double-digit performance. Q1 FY27 was a soft quarter due to timing shifts in deliveries; business is cyclical with lumpiness expected in quarterly performance.
What is Anthem Biosciences Ltd share price analysis?
Anthem Biosciences Ltd currently shows a below-average growth signal. The stock trades at a P/E of 88.2 with a market cap of ₹52,306 Cr. Investors should review the full earnings analysis for detailed insights.
Keep Anthem Biosciences Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
